A Dose-range Study to Assess the Safety & Immunogenicity of a Novel HPV Vaccine When Administered Intramuscularly According to a 3-dose Schedule (0,1,6-mth) in Healthy Adult Females (18-25 Yrs of Age)
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
Evaluation of immune response of the novel HPV vaccine at different dosages at month 7.
GSK Clinical Trials
Belgium: Federal Agency for Medicines and Health Products, FAMHP
|GSK Investigational Site||Aurora, Colorado 80012|
|GSK Investigational Site||Cranston, Rhode Island 02920|
|GSK Investigational Site||Salt Lake City, Utah 84107|